Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 784.45

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	2/10/2015 8:00:49 AM
	Read Replies (1) of 3559

REGN Q and 2014 earnings... files.shareholder.com - "Fourth quarter 2014 EYLEA® (aflibercept) Injection global net sales increased 39% to $815 million (consisting of $518 million in the U.S. and $297 million in rest of world(1) ) versus fourth quarter 2013 - Full year 2014 EYLEA global net sales increased 48% to $2.78 billion (consisting of $1.74 billion in the U.S. and $1.04 billion in rest of world(1) ) versus full year 2013 - Fourth quarter 2014 non-GAAP net income(2) increased 27% to $328 million, or $2.79 per diluted share. Full year 2014 non-GAAP net income(2) increased 26% to $1.17 billion, or $10.00 per diluted share." Earnings short of consensus but revenues beat. Nice ramp on EYLEA ex US. Anyone know what the target is for the "life threatening infection"?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next